anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a queuing method for realizing individual traversal of a plurality of parallel processes by applying an information technology. Belongs to the field of information technology application. Such as: the service process of a service main body consists of a plurality of parallel sub-processes, and a served party completes an agreement between the two parties by traversing each service sub-process and a window thereof. For example, physical examination, the served individual needs to randomly and repeatedly go through a plurality of physical examination items. The problem that occurs in such events is that the service personnel are intensively concentrated and are repeatedly queued in each sub-process, so that the time and the service space are inefficiently occupied. Currently, most do not use information technology to implement such service queuing. The invention realizes the first-level queuing and the second-level queuing by setting and using the right 1, the right 2 and the right 3 and matching with the array stored in the subarea, thereby realizing the homogenization of the intensive personnel, eliminating the repeated queuing and releasing the invalid occupation.
Use of SNRIs, including DRIZALMA SPRINKLE, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)]. In male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SNRI use may result in decreased libido and delayed or absent orgasm.

It is important for prescribers to inquire about sexual function prior to initiation of DRIZALMA SPRINKLE and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.
Patients receive copanlisib hydrochloride IV over 1 hour on days 1 and 15 or days 1, 8, and 15 depending on dose level and olaparib PO BID on days 1-28 of each cycle. Beginning cycle 2, patients receive durvalumab IV over 1 hour on day 1 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples at baseline within 7 days of C1D1, days 8 and 15 of cycle 1 and day 15 of subsequent cycles, at time of restaging, and end of treatment/progression. Patients undergo x-ray, CT, and MRI at the end of cycle 2 and then every 8 weeks. Patients also undergo an ECHO during pre-study within 28 days of C1D1 and tumor biopsy at baseline within 7 days of C1D1 and day 15 of cycle 1 or 2, and may undergo an optional biopsy at end of treatment/progression.
The rate of gestational diabetes and fetal macrosomia is increasing. Moreover, it appears that many macrosomic infants are born to non-diabetic mothers. However, this presents the question of whether our current accepted means of diagnosis is reflecting the true prevalence of GDM. The 3-hour GTT measures glycemic control over a limited period of time. A more prolonged period of monitoring makes more physiologic sense, as it would paint a picture of a patient's overall trend before a diagnosis can be confirmed or excluded. Given the ability of the CGMS and capillary glucose monitor to follow glycemic trends over an extended time period, these methods may prove more effective at identifying patients with abnormal glucose tolerance. As these modalities test the patients in their native environments, the effect of dietary changes prior to the testing period may be minimized, potentially providing an more accurate assessment of abnormal glucose utilization. Furthermore, both modalities should be more cost-effective than the 3- hour GTT.
BACKGROUND AND OBJECTIVES: Acute appendicitis is one of the most commonly encountered surgical emergencies on a global level. Due to the requirement of an immediate clinical diagnosis and the presence of limited resources, clinicians and diagnosticians refer to scoring systems to diagnose this condition, among which Alvarado and Tzanakis scoring systems are widely used. This meta-analysis aims to compare the diagnostic accuracy of these two systems.
METHODS: We searched PubMed, Google Scholar, and SCOPUS databases. All studies that reported diagnostic parameters of Alvarado and Tzanakis scores in patients with suspected acute appendicitis were selected. Diagnostic values such as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were extracted from the selected studies and statistical analysis was performed with Meta Disc 1.4 software. Quality assessment of the selected studies was performed using the QUADAS-2 and QUADAS-C tools. Fourteen studies were included in our meta-analysis which enrolled 2235 patients.
RESULTS: The overall sensitivity of the Tzanakis score was calculated as 0.86 (95% CI; 0.84-00.87) while the specificity was 0.73 (95% CI; 0.69-0.78). In addition, the area under the curve (AUC) was 0.9261 (SE; 0.0169) and the diagnostic Odds Ratio (OR) was 22.52 (95% CI; 9.47-53.56). The pooled sensitivity of Alvarado score was 0.67 (95% CI; 0.65-0.69) and the specificity was 0.74 (95% CI; 0.69-0.79). Moreover, the area under the curve (AUC) of the Alvarado score was 0.7389 (SE; 0.0489) and the diagnostic Odds Ratio was 4.92 (95% CI; 2.48-9.75).
INTERPRETATION AND CONCLUSION: The Tzanakis scoring system has a higher sensitivity, area under the curve, and diagnostic odds ratio when compared to the Alvarado score. However, the Alvarado score has a marginally better specificity making it more reliable in excluding acute appendicitis.
The goal of this substudy is to determine if a brief single-session-intervention (SSI) coupled with different incentive strategies to support engaging in wellness-related activities. Participants will be given a brief SSI that will provide education and strategies to improve a wellness related goal (e.g., improve sleep, improve physical activity, improve mental health). They will then be asked to select a series of wellness related-behaviors in support of that goal to complete each day (e.g., going for a 20 minute walk, going to bed at a specific time). Participants will be randomized to one of four incentive conditions and receive rewards based on their completion of such activities. The aim of the study is to determine which incentive strategy may prove most effective in promoting wellness behaviors. There are two main factors (Recipient x Restoration) that will create four distinct groups. Recipient refers to who will receive the incentive - either an individual or a charity. Restoration refers to what happens when a participant misses a day of completing their goal - they are given a restorative (additional) incentive to participants on the following day or not given such an incentive. The primary hypothesis is that individuals receiving the incentive with a restorative element will result in significantly more activities completed. Additional hypotheses regarding differences among the other groups are not made given the lack of prior work on these strategies in this area.
1468402 Triarylphosphonium salts F HOFFMANNLA ROCHE & CO AG 29 March 1974 [30 March 1973] Divided out of 1468401 09185/76 Heading C2P The invention comprises triaryl phosphonium salts of the general formula wherein R 1 and R 2 each represent a lower alkyl group, R 3 represents a hydrogen or halogen atom or a lower alkyl, lower alkoxy, lower alkenoxy, nitro, amino, mono(lower alkyl)- amino, di(lower alkyl)amino, lower alkanoylamino or N-heterocyclic group, R 4 represents a lower alkenyl, lower alkoxy, lower alkenoxy, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkanoylamino or N-heterocyclic group and R 5 represents a hydrogen or halogen atom or a lower alkyl, lower alkenyl, lower alkoxy, lower alkenoxy, nitro, amino, mono(lower alkyl)amino, di(lower alkul)amino, lower alkanoylamino or N-heterocyclic group provided that when R 3 or R 5 is a halogen atom R 4 is other than a lower alkoxy group, m is 0 or 1, X is aryl and Y is the anion of an organic or inorganic acid, the lower alkyl, lower alkenyl, lower alkoxy, lower alkenoxy, and lower alkanoyl groups being defined as those containing up to 6 carbon atoms in each case. The aryl group X includes C 1 -C 6 alkylphenyl and C 1 - C 6 alkoxyphenyl and the preferred anions Y are Cl, Br, I, hydrosulphate and tosyloxy. Specified N-heterocyclic groups are pyrrolidino, piperidino, morpholino and thiamorpholino. The compounds in which m is zero and Y is a halide anion may be obtained by treating a corresponding (R 1 -R 5 )-benzene with formaldehyde in the presence of a hydrohalic acid, e.g. cone. HCI, if desired in a solvent and reacting the resulting (R 1 -R 5 )-benzyl halide with a triaryl phosphine in a solvent. Compounds in which m is 1 and Y is a halide anion can be obtained by reacting a formylating agent with the corresponding (R 1 - R 5 )-benzene, e.g. by reaction with orthoformic acid, formyl chloride or dimethyl formamide in the presence of a Lewis acid, reacting the resulting (R 1 -R 5 )-benzaldehyde with acetone in the presence of alkali to form a 4-(R 1 -R 5 )-phenylbut-3-en-2-one, converting the latter to the corresponding acetylenic alcohol (5-(R 1 -R 5 )- phenyl - 3 - methyl - 3 - hydroxy - penta - 4 - en- 1-yne) by a Grignard reaction with addition of acetylene, partially hydrogenating the acetylenic alcohol to form the corresponding diolefinic alcohol and then converting the latter to a triarylphosphonium salt by treating with a triaryl phosphine in the presence of a hydrohalide, e.g. HCl or HBr, in a solvent, e.g. benzene. The products are useful as intermediates in the production of polyene derivatives having therapeutic properties. (From GB1468402 A) [FR2223037A1]
PURPOSE: A process for maximumly extracting an active component contained in a seed of Taxus cuspidata Sieb. et Zucc. by optimizing the extraction condition thereof is provided. Thus obtained Taxus cuspidata seed extract and seed oil thereof exhibit antioxidant and anti inflammatory effects so that it can be effectively used in a cosmetic. CONSTITUTION: An anti-skin aging cosmetic composition having antiinflammatory and antioxidant effects contains 0.001 to 20% by weight of a component selected from a Taxus cuspidata seed extract, Taxus cuspidata seed oil and a mixture thereof as an effective ingredient. About 10 to 30% by weight of dried Taxus cuspidata seed is extracted in a solvent containing 20 to 30% by weight of butylene glycol, 20 30% by weight of propylene glycol and the balance of purified water at 20 to 50deg. C, while agitating at 500 to 2,000rpm for 1 to 4hr and filtered after cooling to 20 to 40deg.C.
Taxanes are the most widely tested and effective chemotherapy drugs for hormone refractory prostate cancer. Weekly paclitaxel was reported to produce 25-39% PSA responses in first line and up to 33% in second line chemotherapy of patients with prostate cancer in early clinical trials (1, 2). Paclitaxel activity in prostate cancer is schedule dependent, and weekly paclitaxel was reported to produce highest response rates (1, 2). Docetaxel was recently approved by the Food and Drug Administration for treatment of hormone refractory metastatic prostate cancer, since it is the only chemotherapy drug with documented improvement in survival in this group of patients. Docetaxel was associated with 45.8% overall grade 3/4 toxicities and it has to be given with steroid pre-medication. This regimen might be difficult to use in advanced prostate cancer patients that are often elderly and with multiple co-morbid conditions.

ABI-007 \[Abraxane™ (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)\] is the first in its class of biologically interactive albumin-bound forms of chemotherapy (3). This composition provides a novel approach of increasing intra-tumoral concentration of the drug by a receptor-mediated transport process allowing transcytosis across the endothelial cell wall, thereby breaching the blood/tumor interface. This albumin-specific receptor mediated process involves the binding of a specific receptor (gp60) on the endothelial cell wall, resulting in activation of a protein caveolin-1, which initiates an opening in the endothelial wall with formation of a little caves or caveolae, with transport of the albumin-bound chemotherapeutic complex via these caveolae to the underlying tumor interstitium (4). A protein specifically secreted by the tumor (SPARC) binds and entraps the albumin, allowing release of the hydrophobic drug to the tumor cell membrane. ABI-007 is the first biologically interactive albumin-bound chemotherapy agent leveraging this gp-60/caveolin-1/caveolae/Sparc pathway to increase intra-tumoral concentration of the drug and reduce the amount of the toxic chemotherapy in normal tissue.

Preclinical studies comparing Abraxane to paclitaxel demonstrated lower toxicities, with a maximum tolerated dose (MTD) approximately 50% higher for Abraxane (7) compared to paclitaxel (11). At equal doses there was less myelosuppression and improved efficacy than paclitaxel in a xenograft tumor model of human mammary adenocarcinoma. Clinical studies confirmed improved toxicity profile and higher response rates, in metastatic breast cancer, of Abraxane compared to cremophor EL paclitaxel (Taxol) (5, 8). The weekly regimen was shown to be active even in patients with cancers refractory to paclitaxel, docetaxel or when Abraxane was given after both agents (8).
Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
Intervention with Expressive Interviewing computer system. Participants spent roughly 10-15 minutes each in conversation with an automated computer chat system. Participants answered a survey about mental health and social outcomes immediately before the intervention and two weeks after the intervention.
Immunoparalysis is an immunosuppressed state that occurs after a wide variety of insults including sepsis and cardiopulmonary bypass surgery. Due to the impaired infection fighting ability, patients with immunoparalysis are at risk of subsequent infection which can increase mortality. Immunoparalysis can be measured by two methods: 1) ex vivo endotoxin stimulation and 2) blood monocyte HLA-DR levels. Since sepsis is also a known complication of Acute Kidney Injury(AKI), the investigators hypothesize that AKI is a risk factor for immunoparalysis. The investigators plan to look at these blood factors of immune function from patients before and 3 days following cardiac surgery. Urine will also be collected from the patients before their surgery as well as the 3 days following for AKI biomarker measurement. This prospective cohort will enroll 300 patients and determine the duration and severity of immunoparalysis among patients who develop AKI and those who do not develop AKI.
The fast growth of so-called Decision Neuroscience has clearly shown the implications of methods and results from behavioral economics as a potential bridge for translational research in neuro-psychiatric settings. The combination of behavioral and neural metrics allows to describe decision-making across multiple levels of explanation ranging from biological dispositions to contextual influences. To date, however, the translational implications of Decision Neuroscience are constrained by a relatively limited knowledge of the potential modulators of decision-making, which seem to include perceptual, cognitive and motor variables. In this regard, there is largely sparse evidence concerning the modulation of choices by highly different factors such as a) perceptual features of the stimuli (e.g., spatial distance between visually-presented potential gains and losses); b) type of processing required to participants (e.g., select vs. reject an option); c) type of motor response required to communicate the decision (e.g., press vs. release a button); d) subliminal vs. supraliminal perception of the stimuli. Moreover, there is evidence of ageing effects on decision-making, particularly when choice-related evaluations involve a trade-off between reward and risk. On this ground, this single center non-interventional behavioral study aims to investigate whether, and how, distinct well-established metrics of decision-making are influenced by the aforementioned factors. To this purpose, 200 healthy individuals will be recruited and assigned to different behavioral studies aimed to assess the effect of the aforementioned manipulations on well-established gambling tasks resulting in individual metrics of loss aversion (the tendency to prefer avoiding losses to acquiring equivalent gains), risk aversion (the preference for certain outcomes over probabilistic ones), and delay discounting (the decline in the present value of a reward with delay to its receipt). The results of this study are expected to provide a baseline reference for assessing alterations of decision-making performance in pathological conditions.
Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
Group B (n=30) will receive an asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted. The micro-video will be provided on a 12.9-inch iPad pro for each participant to view individually. The micro-video group will also have the opportunity to practice pump refilling before the post-evaluation. Participants in Group B will have the micro-video instruction available while practicing hands-on baclofen pump refilling and programming. The maximum time allowed to view the micro-video and practice hands-on baclofen pump refilling and programming will be 30-minutes. The time that each participant in group B spends reviewing the micro-video and practicing hands-on pump refilling and programming will be recorded. The participant may view and rewind the video as many times as needed in the 30-minute period. The live demonstration and the procedural video describe identical steps involved in refilling and programming the baclofen pump.
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.
The need for evidence-based mental health treatments i.e., 'treatment based on the best available science or research evidence"1, has been stressed from scientific, ethical, and marketing perspectives. While empirical evidence supports both the efficacy and effectiveness of cognitive behavior therapy (CBT) for Obsessive-Compulsive Disorder (OCD), demand for clinicians trained in these approaches far exceeds supply. New technologies provide the opportunity to facilitate access to this specialized treatment. A growing body of research has found that web-based self-administered psychotherapy is highly effective, cost-efficient, and can achieve clinical improvements similar to those obtained with clinician administered therapy. The long-term goal of this project is to improve clinical and occupational functioning and decrease disability associated with OCD by improving access to effective treatments through the use of web-based CBT treatment. The intervention involves a computer program (BT STEPS) and human interaction via telephone. The inclusion of human interaction for coaching and encouragement has been found to significantly increase compliance and success rates in computerized self-help. Whether treatment outcomes differ when this coaching is done by a therapist versus when done by a trained non-therapist has not been studied. This is the first program to examine a hybrid model involving different levels of remote clinician coaching in combination with an on-line self-help tutorial. In Phase I the investigators will test the efficacy and feasibility of computer therapy alone (n=35), computer plus nontherapist coach (n=35) and computer plus CBT therapist coach. In phase II the investigators will do a fully powered study comparing our model to traditional face-to-face therapy.
Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.